Savara Misses FDA Date for Molgramostim Review

The FDA will not meet its November 22, 2026 target action date for Savara's molgramostim application for autoimmune pulmonary alveolar proteinosis.

Updated on Nov. 20, 2026 in Biotech

Isometric editorial illustration of a cream and slate nebulizer device on an oxblood surface with a sand-timer silhouette behind it, suggesting a paused review timeline.
The FDA will not meet its November 22, 2026 target action date for Savara's molgramostim application for autoimmune pulmonary alveolar proteinosis, and has not set a new date. AI Illustration. Upload story photo >

The U.S. Food and Drug Administration will not meet the November 22, 2026 target action date for Savara Inc.'s Biologics License Application for molgramostim, an investigational treatment for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The FDA has not provided a revised action date, and the review remains ongoing.

Why it matters

Molgramostim is not approved by the FDA or any other regulator, and its safety and efficacy have not been established, so the delay leaves patients with autoimmune PAP without a new option for now. The missed date extends the timeline for a decision on whether the therapy will reach the U.S. market.

The figure is the November 22, 2026 PDUFA target date, announced by Savara on November 20, 2026. The FDA has not provided a revised action date, and the reason for the missed deadline has not been disclosed.

The players

Savara Inc.

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases.

Matt Pauls

Matt Pauls is the chief executive of Savara Inc., which is based in Yardley, Pennsylvania.

The details

Savara said the FDA communicated that it would not meet the target action date for the molgramostim BLA, which is for autoimmune PAP. Molgramostim is an investigational recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System made by PARI Pharma GmbH.

Timeline

  1. November 20, 2026: Savara announces the FDA will not meet the PDUFA date.

  2. November 22, 2026: Original PDUFA target action date for the molgramostim BLA, now missed.

Regulatory Context

Under the PDUFA review clock, the FDA typically acts by the target action date, so a missed date like this one for molgramostim is a departure from the expected timeline for this application.

For people living with autoimmune pulmonary alveolar proteinosis, the delay means molgramostim is not yet available as a treatment option. Savara said it looks forward to working closely with the FDA to complete its review.

The takeaway

A missed PDUFA date does not signal a decision on the drug itself, but it does mean patients and investors should watch for a revised FDA timeline. The outcome of the review remains open until the agency acts.

Further reading

Track more developments in Biotech news from across the United States.

Source note: This article includes information reported by Firstwordpharma.